These include standards for verifying equivalent safety and quality standards, which in half of the Member States go beyond the requirements of the EU blood legislation, e.g. adding requirements for the use of the more sensitive nucleic acid testing (NAT) now available as a routine test for hepatitis and HIV screening.
Näiteks on lisatud nõuded kasutada tundlikumaid nukleiinhapete põhiseid uuringuid (nucleic acid testing, NAT), mis on praegu rutiintestidena kättesaadavad hepatiidi ja HIV sõeluuringuks.